

Life Saving technology for effective **chest drainage** and **chest trauma diagnosis**

Company Presentation

EIC Info Day

November 2024



The Problem

Chest trauma and effective drainage

20 M

Chest Trauma
cases

3rd

Leading cause
of death

62 M

Thoracic and Abdominal
Procedures



Golden Hour = 80% Survival

CURRENT SOLUTIONS and ITS DRAWBACKS:




- Effective treatment (4M/Year): chest tubes insertion by doctor
- Up to 40% complications
- Re-interventions (4K Euro/Procedure)
- No definite/effective solution pre-hospital
- **Forecasted CAGR: 5.3%** by 2030

The C-LANT Solution

C-LANT facilitates any CHEST TRAUMA treatment and POSTOPERATIVE DRAINAGE

- ✓ Feasibility proven in Lab and in-vivo (animals)
- ✓ Transfer from R&D to mass production Completed
- ✓ Manufacturing of final products batch in progress for V&V testing
- ✓ IP protected (US 10857341B2. EP 17 776 751.4)

https://www.youtube.com/watch?app=desktop&v=4xgad_-O8oU



C-LANT Unique Value Proposition

Customers: healthcare institutions (EMS, Trauma Centers & Hospitals)

- ✓ >€2.6B savings due repeated procedures, disposables & procedure time (EU)
- ✓ Self-fixating, easy tube replacement

End-users: paramedics and doctors


- ✓ Enabling for less qualified medical personnel pre-hospital
- ✓ A-traumatic, 10 sec. fixation

Beneficiaries: patients

- ✓ Increases by 80% the chance of survival in the golden hour
- ✓ Less-traumatic device

Competitive Landscape

C-Lant is the only self-fixating, easy to use and safe effective device for drainage








**C-Lant
Port**

**Chest Tube
Gold Standard**

Decompression Needle

**Chest
Seal**

Self Fixation	 Sec., automatically adjusts
User Friendly	 Incl. Nurses, paramedics
Hermetic Seal	 For any size tube
Cost Effective	 No replacement
Safe Insertion	

X

X

X

X

X

X

X

X

X

X

X


X

X

X




Market Opportunity for C-Lant Port




TAM: All C-Lant Indications
SAM: Thoracic Drainage Only

SAM Segmentation (MM Euros)



Main drivers


- ✓ Rising Ageing Population (Falls, Lung Diseases)
- ✓ Wars, climate driven disasters
- ✓ Few Innovative Solutions



New Product: AI-Powered App for US/Digital Stethoscope injury diagnostics



Examination of hemothorax/pneumothorax with the help of portable ultrasound by paramedics in the ambulance



The Team

We are a multidisciplinary team with >200 Years of combined experience with proven capabilities in bringing innovative products from concept stage to commercialization.



Irina Kavounovski
CEO, Co-Founder
 20+ Years of Management & BD experience in MedTech companies, VCs and Hospitals



Igor Waysbeyn
CTO, Co-founder
 Mechanical Engineer with Medical Background, R&D Leader for 35+ years, 15 Patents



Dr. John Abeles
Co-Founder
 MD, 40 years of experience in private/public Healthtech companies. >10 Exits



Amir Chacham
CFO
 CPA (M&A, Fundraising and financial management) Auditor EY



Dr. Avi Hirsch
Director BD
 EMT-P, PhD with 20 years of global experience in medical device industry




Dr. Oved Cohen
CMO (Medical)
 Highly experienced cardiac surgeon with distinguished career in Israel & USA.



Scientific Advisory Board

- Prof. Arik Eizenkraft (Military, EMS)
- Prof. Lenworth Jacobs (EMS)
- Prof. Lev Muchnic (AI)
- Dr. I. Koifman (ICU)
- Dr. E. Solomonov (Abdominal Surgery)
- Dr. Ralf Kolvenbach (Surgery)
- Dr. S. Abeshaus (Neurosurgery)

Road to Market




Business Model and Projections

B2B2B, B2G, Indirect sales, 50% margin

Royalties for Emergency Kits

Prices (€): COGS (15), Transfer (90), End user (180)



2025: Sales Launch (USA)


2026: Sales Launch (Europe)

2027 Operational Profitability

2030 >700K Units sold/year, with 98M
Euros Revenues

The Ask

Expenses



- **Current Round A, Euros: 2MM**
(co-investment milestone)
Main milestones: FDA, CE Mark and ISO 13485, market launch, V&V testing incl. clinical trial
- **Previous Funding (Euros): 3.3MM**
EIC grant (1.7 MM received out of 2.5MM) , Israeli non-dilutive grants, Revenues, Prizes and Investments

Contact

Vigor Medical

irina@vigormt.com

Irina Kavounovski, CEO

Tel (IL): +972 52 6462215

Tel (CZ): +4204646070

www.vigormt.com

